📣 VC round data is live. Check it out!

Provectus Valuation Multiples

Discover revenue and EBITDA valuation multiples for Provectus and similar public comparables like Teneo AI, Insig AI, Substrate Artificial, Lighton and more.

Provectus Overview

About Provectus

Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (HXs). Its HX molecule is named rose bengal sodium. The company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of its current clinical development programs and the preclinical formulations of its current drug discovery programs.


Founded

2002

HQ

United States

Employees

6

Financials (FY)

Revenue:
EBITDA: ($5M)

EV

$30M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Provectus Financials

Provectus reported last fiscal year revenue of — and negative EBITDA of ($5M).

In the same fiscal year, Provectus generated ($5M) in EBITDA losses and had net loss of ($6M).


Provectus P&L

In the most recent fiscal year, Provectus reported revenue of and EBITDA of ($5M).

Provectus is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.

See analyst estimates for Provectus
Last FY202320242025202620272028
EBITDA($5M)($3M)($5M)($5M)
Net Profit($6M)($3M)($5M)($6M)
Net Debt$3M

Financial data powered by Morningstar, Inc.

Provectus Stock Performance

Provectus has current market cap of $27M, and enterprise value of $30M.


Provectus' stock price is $0.06.

Provectus has an EPS (earnings per share) of $-0.01.

See more trading valuation data for Provectus
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$30M$27M0.0%$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Provectus Valuation Multiples

Provectus trades at (5.6x) EV/EBITDA.

See NTM and 2027E valuation multiples for Provectus

Provectus Financial Valuation Multiples

As of May 10, 2026, Provectus has market cap of $27M and EV of $30M.

Provectus has a P/E ratio of (4.9x).

Last FY202320242025202620272028
EV/EBITDA(5.6x)(10.3x)(6.6x)(5.6x)
EV/EBIT(5.6x)(10.1x)(6.5x)(5.6x)
P/E(4.9x)(8.7x)(5.6x)(4.9x)
EV/FCF(8.9x)(11.5x)(9.0x)(8.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Provectus Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Provectus Margins & Growth Rates

See estimated margins and future growth rates for Provectus

Provectus Growth Rates

23/2424/2526/2727/2828/29
EBITDA Growth57%17%
EBIT Growth55%17%
Net Profit Growth54%16%
FCF Growth28%1%

Data powered by FactSet, Inc. and Morningstar, Inc.

Provectus Operational KPIs

Provectus' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.

Access forward-looking KPIs for Provectus
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$0.9M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Provectus Competitors

Provectus competitors include Teneo AI, Insig AI, Substrate Artificial, Lighton, Datrix, Helport AI, Satsuma Technology, OODA AI, Rocket Doctor AI and Ayfie International.

Most Provectus public comparables operate across Pure-Play AI Software and Generative AI.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Teneo AI5.9x(20.0x)
Insig AI39.7x(3.5x)
Substrate Artificial1.6x2.4x
Lighton20.2x9.0x(5.4x)(4.2x)
Datrix1.8x2.5x23.0x16.3x
Helport AI1.1x5.6x
Satsuma Technology123017.6x(173.8x)
OODA AI3.9x(1.1x)

This data is available for Pro users. Sign up to see all Provectus competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Provectus

When was Provectus founded?Provectus was founded in 2002.
Where is Provectus headquartered?Provectus is headquartered in United States.
How many employees does Provectus have?As of today, Provectus has over 6 employees.
Is Provectus publicly listed?Yes, Provectus is a public company listed on OTC Pink Sheets.
What is the stock symbol of Provectus?Provectus trades under PVCT ticker.
When did Provectus go public?Provectus went public in 1997.
Who are competitors of Provectus?Provectus main competitors include Teneo AI, Insig AI, Substrate Artificial, Lighton, Datrix, Helport AI, Satsuma Technology, OODA AI, Rocket Doctor AI, Ayfie International.
What is the current market cap of Provectus?Provectus' current market cap is $27M.
Is Provectus profitable?No, Provectus is not profitable.
How many companies Provectus has acquired to date?Provectus hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Provectus has invested to date?Provectus hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Provectus

Lists including Provectus

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial